Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

OncoImmune cleared to begin phase III study of CD24Fc for hospitalized patients with COVID-19

April 9, 2020

Butantan-DV demonstrates safety and immunogenicity in phase II study

April 9, 2020

Discovery of a novel antimalarial compound, CHMFL-PI4K-127

April 9, 2020

Enanta Pharmaceuticals identifies compounds for HBV infection

April 9, 2020

Thomas Jefferson University develops COVID-19 vaccine candidate

April 9, 2020

Active compound of WP-1122 reduces coronavirus replication in vitro

April 9, 2020

Novavax to initiate first-in-human studies of its new coronavirus candidate

April 9, 2020

Viriom opens phase II study of NNRTI elsulfavirine for COVID-19

April 8, 2020

Emapalumab and anakinra studied to reduce hyperinflammation and respiratory distress in COVID-19

April 8, 2020

New nitrofuran-class antibiotic IITR-06144 shows efficacy against resistant bacteria

April 8, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....